Moderate to severe eczema (atopic dermatitis)
A study of camoteskimab, an investigational medicine given as an injection under the skin, in adults whose eczema has not been controlled by creams and ointments, or for whom those treatments are not advisable.
- Who may qualify
- Adults 18 to 65 who have had eczema for at least a year, covering at least 10% of the body, with itch that rates at least 4 out of 10. Other requirements apply; the research team reviews the full list with you.
- How it works
- For the first 24 weeks, participants are assigned by chance to one of three doses or a placebo, an injection with no active medicine, and neither you nor the study team knows which. After that, everyone receives camoteskimab.
- Study stage
- Phase 2b, sponsored by Apollo Therapeutics.


